Previously, Vincerx had revealed plans for a reverse triangular merger with QumulusAI, which would have made QumulusAI a publicly traded entity. In another development, Vincerx Pharma and Oqory ...

April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse stock ...

A young Peninsula drug developer with less than $5 million in hand will wind down its operations after its attempt at a reverse triangular merger fell apart. Vincerx Pharma Inc. (Nasdaq ...

This decision follows the recent stockholder approval of Aerovate’s merger with Jade Biosciences, Inc. The reverse split is scheduled in anticipation of the merger’s completion, with the ...

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), currently trading at $2.75, announced on Monday that its board of directors has approved a 1-for-35 reverse stock split. This decision follows the recent ...

the expected number of shares of common stock to be issued and outstanding following the reverse stock split and the Merger, and other statements regarding management’s intentions, plans ...

Previously, Vincerx had revealed plans for a reverse triangular merger with QumulusAI, which would have made QumulusAI a publicly traded entity. In another development, Vincerx Pharma and Oqory ...

The change will follow the anticipated closing of Cara’s merger with Houston-based Tvardi, which is privately held. Cara’s stockholders approved the reverse stock split during a special ...